AI Cytology and Digital Pathology
Founded in 2000, Landing Med is a medtech company focused on early cancer detection solutions. We offer affordable and accessible AI-powered cytology & digital pathology technologies to empower laboratories worldwide to enhance diagnostic precision, efficiency, and confidence. As a globally recognized leader in cervical cytology screening, we have successfully screened over 10 million women and strive to make pathology accessible to all.
Read More
Our  Products
Global Publications
In the Press
Landing Med Certifications
Our Partners
Portable Digital Pathology
Slide Scanner
LD Patho 320
High Throughput Digital  Pathology Slide Scanner
LD Cyto2200
Al Cervical Cytology Screening System
Al Cervical
2023, The Lancet Regional
Health-Western Pacific
Cost-effectiveness of artificial intelligenceassisted liquid-based cytology testingfor
cervical cancer screening in China
Read More
2021, Cervical Cancer
Role of Al in Cervical Cancer Screening
The artificial intelligence-assisted cytology diagnostic system in large-scale cervical cancer screening: A population-based cohort study of 0.7 million women
2020, Cancer Medicine
See all Global Publications >
Chinese Medtech Company Landing Med Surpasses 10 Million AI-Assisted Pap Smear Screenings
Smart screening broadens cervical cancer monitoring
Foreword: Accelerating Cervical Cancer Prevention and Control in China to Achieve .....
AI boosts cervical cancer diagnoses